Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 15.69B

MomentumView details →

1D Return

−2.02%

YTD Return

+46.65%

RSI (14)

52.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 15.69B

RSI (14)

52.0

MomentumView details →

1D Return

−2.02%

YTD Return

+46.65%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Haixi New Drug (02637.HK) reported interim results for the six months ended June 2026, with revenue of RMB 312 million, up 3.9% year-on-year, and net profit attributable to shareholders of RMB 81.05 million, down 24.8%.5d ago

Haixi New Drug's candidate drug molecule HX9428 was granted Fast Track designation by the U.S. FDA for the treatment of neovascular age-related macular degeneration.18d ago

Similar companies

Neurocrine Biosciences, Inc.NBIX 步长制药603858.SH 华润双鹤600062.SH 健康元600380.SH 华润江中600750.SH Grand Pharmaceutical Group Limited00512.HK Find similar companies →

Latest newsMore news →

Haixi New Drug (02637.HK) reported interim results for the six months ended June 2026, with revenue of RMB 312 million, up 3.9% year-on-year, and net profit attributable to shareholders of RMB 81.05 million, down 24.8%.5d ago Haixi New Drug's candidate drug molecule HX9428 was granted Fast Track designation by the U.S. FDA for the treatment of neovascular age-related macular degeneration.18d ago Haixi New Drug (02637) announced that it has officially initiated a second Phase II clinical study of HX9428 for treating nAMD in China, with the registration information disclosed on the NMPA CDE platform.31d ago